BlueAllele Corporation Receives Patent for Advanced Gene Editing Technology

Oakdale, Minnesota, August 17, 2021 — BlueAllele Corporation, a biotechnology company focused on advancing transformational gene correction technologies, announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,091,756 (the ‘756 Patent), directed to the use of BlueAllele’s foundational PALIDON^® technology.

BlueAllele’s PALIDON repair templates feature a palindromic, bi-directional structure that is designed to leverage the high rate of non-homologous end joining (NHEJ) repair observed in cells, while preserving the ability to achieve precise correction of damaged mRNA and protein. PALIDON repair templates are designed to be compatible with existing gene editing nucleases and delivery systems, making PALIDON particularly suitable for targeting an expansive number of loss-of-function and gain-of-function monogenic diseases.

The palindromic design of PALIDON converts what was previously a byproduct (reverse integration) into a functional event that contributes to enhanced efficacy. By integrating PALIDON within introns, any potential error introduced by the NHEJ pathway can be tolerated, thereby minimizing unwanted byproducts. PALIDON captures the natural expression from an endogenous gene, resulting in exceptional control of protein levels with stable and durable edits.

“We are pleased that the USPTO has recognized the significance of our PALIDON technology and granted this patent. Protecting intellectual property is a critical part of our business model, particularly as we continue to develop novel and innovative methods for achieving precise gene correction,” said Dr. Nicholas J. Baltes, BlueAllele’s chief scientific officer. “Further, the grant of this new patent highlights the unmet need for improving the precision, efficacy and versatility of insertion-based gene editing techniques.” As the examiner of the ‘756 Patent noted, PALIDON“… expands the field of CRISPR technology in a novel way that was not recognized by prior researchers in this area.”

The ‘756 Patent includes claims covering methods for using PALIDON to edit genes. In addition, the issued claims cover the use of PALIDON in any cell type and system (e.g., animal cells for in vitro or in vivo applications), as well as its use for correcting any gene in the genome, providing broad coverage for its use in the development and advancement of human gene correction technologies.

“This patent demonstrates our expertise and commitment to unlocking the full potential of gene editing for treating genetic diseases,” said Joseph B. Saluri, BlueAllele’s chief executive officer. “We are excited to continue advancing our PALIDON platform, along with the other innovative gene correction technologies in our R&D pipeline.”

The ‘756 Patent was developed by and is exclusively owned by BlueAllele Corporation.

Media Contact

Makayla Smith
515-974-4736
msmith@trilix.com